{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073377","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.161490+00:00","generated_at":"2026-05-15T23:43:00.742276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom reports Q4 revenue $57.6M, FY2025 revenue $175.1M (+217% YoY); expects operating profitability in Q3 2026","bullets":["Q4 net revenues $57.6M; FY2025 net revenues $175.1M, a 217% increase over FY2024.","Q4 GAAP net loss narrowed to $21.1M from $74.5M in Q4 2024.","Non-GAAP adjusted net loss for Q4 was $5.7M, improved from $56.4M in Q4 2024.","Expects operating profitability beginning Q3 2026 and for FY2026; cash flow positivity in 2027.","Completed $130M equity offering Jan 2026; modified term loan to $175M principal, extended maturity to Feb 2029; pro forma cash ~$190M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073377","json":"https://secwatch.observer/filing/0001193125-26-073377.json","markdown":"https://secwatch.observer/filing/0001193125-26-073377.md","text":"https://secwatch.observer/filing/0001193125-26-073377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/0001193125-26-073377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/d119012d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:43:00.742276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}